DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine

Documenti analoghi

• Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
  di: Voutsas, Ioannis F., et al.
  Pubblicazione: (2016)
• MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells
  di: Anastasopoulou, Eleftheria A., et al.
  Pubblicazione: (2016)
• Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
  di: Baxevanis, Constantin N., et al.
  Pubblicazione: (2020)
• Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
  di: Mittendorf, E. A., et al.
  Pubblicazione: (2016)
• Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
  di: Sotirios P. Fortis, et al.
  Pubblicazione: (2017-05-01)